Key Highlights

  • Scinai Immunotherapeutics (NASDAQ:SCNI) is listed at USD 1.34, which is 20% above its 52-week low of USD 1.12 and 91.5% below its high of USD 15.80.
  • Scinai's manufacturing subsidiary signed a USD 5.1 million development and clinical manufacturing agreement with a US Nasdaq-listed biopharma on October 13, lifting committed customer orders to about USD 7.6 million, up 300% from year-end 2025.
  • The stock jumped as much as 27% intraday to USD 1.46 from a market value of about USD 786,000 at the prior close, and it regained Nasdaq bid-price compliance on September 21.
  • Scinai raised USD 2.61 million in April, bought Recipharm Israel and ended its PC111 arrangement in September to focus on its NanoAb platform and CDMO.

What Is Moving the Stock

Scinai Immunotherapeutics, a Jerusalem biopharma that also runs a contract development and manufacturing business, announced on October 13 that Scinai Biopharma Services signed a definitive agreement worth about USD 5.1 million in committed base fees for chemistry, manufacturing and controls development and clinical manufacturing of an investigational oncology product. The deal lifts committed customer orders to about USD 7.6 million, a 300% jump from year-end 2025 and more than double the USD 3.1 million reported at August 16, simple arithmetic. The stock rose 15.64% to USD 1.34 on the screen after trading as high as USD 1.46, a 27% gain, in the session.

Short Interest, Volume and the Data

Nasdaq notified Scinai on March 12 of a bid-price deficiency, and the company announced on September 21 that it had regained compliance and the matter was closed. The company raised USD 2.61 million in a private placement on April 24, completed the Recipharm Israel acquisition that added a second manufacturing site in Yavne, and on September 8 ended its PC111 arrangements with PinCell to focus on its NanoAb platform and the CDMO. Prior-close market value was about USD 786,000 per one report, so the USD 5.1 million agreement is roughly six times the company's entire equity value at that point, simple arithmetic. Simple arithmetic puts the prior close near USD 1.16, so the day's move is about USD 0.18 a share. The price sits 20% above its 52-week low and 91.5% below its high, which frames how much of the range has already been used. Volume of 89,304 shares against a three-month average of 1.100 million is 0.1 times, which is light, below average; in a heavily shorted stock, high volume can reflect short covering or new short selling, so volume alone does not reveal direction.

Risks and What to Watch

A micro-cap with a tiny market value, repeated financing needs and one large customer is exposed to dilution and sharp reversals after contract-driven spikes. What to watch next: conversion of the CDMO order book, further financing and short interest data. This is information only and not investment advice. Oil traded above USD 100 a barrel as Russia-Ukraine and Middle East developments and stalled Strait of Hormuz talks kept supply risks elevated.

Where Things Stand

Market conditions frame the day: oil traded above USD 100, the big banks report this week and heavily shorted technology names remain volatile. Scinai Immunotherapeutics (NASDAQ:SCNI) is moving with a USD 5.1 million manufacturing agreement on a very small market value. A gain in a heavily shorted stock can reverse quickly, so the balance of evidence favors waiting for confirmation from filings and the next session. Direction remains unknown, and the next catalyst is conversion of the CDMO order book, further financing and short interest data. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.